Predicted to have phospholipid binding activity. Predicted to be involved in several processes, including cytosolic lipolysis; lipid droplet formation; and regulation of lipid metabolic process. Predicted to localize to endoplasmic reticulum; integral component of endoplasmic reticulum membrane; and lipid droplet. Used to study azoospermia. Human ortholog(s) of this gene implicated in congenital generalized lipodystrophy type 2; distal hereditary motor neuronopathy type 5A; hereditary spastic paraplegia; hereditary spastic paraplegia 17; and lipodystrophy. Orthologous to human BSCL2 (BSCL2 lipid droplet biogenesis associated, seipin); INTERACTS WITH (+)-schisandrin B; 6-propyl-2-thiouracil; bisphenol A.
[schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased expression of BSCL2 mRNA], [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Cisplatin results in increased expression of BSCL2 mRNA]
[7-hydroxystaurosporine results in decreased activity of [CHEK1 protein co-treated with BSCL2 protein]] inhibits the reaction [Aphidicolin results in increased expression of CHEK2 mRNA], [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Aphidicolin results in increased expression of BSCL2 mRNA]
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
[7-hydroxystaurosporine results in decreased activity of [CHEK1 protein co-treated with BSCL2 protein]] inhibits the reaction [Cisplatin results in increased expression of CHEK2 mRNA], [schizandrin B results in decreased activity of ATR protein] inhibits the reaction [Cisplatin results in increased expression of BSCL2 mRNA]
[Benzoapyrene co-treated with benzaanthracene co-treated with benzobfluoranthene co-treated with chrysene] results in increased expression of BSCL2 mRNA
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin
Founder strain for the heterogeneous stock (HS) rat population; SNPs from the RGSC 3.4 assembly were "lifted over" from RGSC 3.4 to Rnor 5.0 and from Rnor 5.0 to Rnor 6.0; Provided by Medical College of Wisconsin